Investors & Media Press Releases

Press Releases

Summary Toggle

08.09.2019

Summary Toggle Axovant Announces Corporate Updates and Financial Results for First Fiscal Quarter Ended June 30, 2019

Summary ToggleSUNRISE-PD Phase 2 trial of AXO-LENTI-PD for Parkinson's disease continues to enroll patients in second dose cohort with data expected in the fourth quarter of calendar 2019 Data from patients dosed with AXO-AAV-GM1 and AXO-AAV-GM2 expected in fourth quarter of calendar 2019 Net loss for the
Read More

PDF Version
Read More
Summary Toggle

07.01.2019

Summary Toggle Axovant Appoints David Nassif as Chief Financial Officer and Expands Board of Directors

Summary Toggle- David Nassif joins executive management team as CFO, effective July 1, 2019 - - Senthil Sundaram to join Axovant’s Board of Directors- BASEL, Switzerland , July 01, 2019 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies,
Read More

PDF Version
Read More
Summary Toggle

06.24.2019

Summary Toggle Axovant Announces Poster Presentations at the 5th Congress of the European Academy of Neurology

Summary Toggle-Details from ongoing SUNRISE-PD Phase 2 trial of AXO-Lenti-PD and AXO-AAV-GM2 program highlighted in poster presentations- BASEL, Switzerland , June 24, 2019 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies, announced two
Read More

PDF Version
Read More
Summary Toggle

06.20.2019

Summary Toggle Axovant and Yposkesi Sign Strategic Gene Therapy Development and Manufacturing Partnership

Summary TogglePartnership secures access to reserved cGMP capacity and resources at Yposkesi for manufacturing to support the global development and commercialization of Axovant’s gene therapy programs BASEL, Switzerland and CORBEIL-ESSONNES, France , June 20, 2019 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd.
Read More

PDF Version
Read More
Summary Toggle

06.11.2019

Summary Toggle Axovant Announces Financial Results and Corporate Updates for Fourth Quarter and Fiscal Year Ended March 31, 2019

Summary ToggleEstablished diversified pipeline of three clinical-stage gene therapy programs for serious neurological disorders including Parkinson’s disease, GM1 gangliosidosis, and Tay-Sachs SUNRISE-PD Phase 2 trial of AXO-Lenti-PD for Parkinson's disease continues to enroll patients in second dose cohort
Read More

PDF Version
Read More
Summary Toggle

06.06.2019

Summary Toggle Axovant Announces 6-Month Follow-Up Data From First Cohort of SUNRISE-PD Phase 2 Trial of AXO-Lenti-PD and Pipeline Update

Summary ToggleAXO-Lenti-PD was observed to be generally well tolerated at six months, and continued to demonstrate benefits in both patients across multiple measures after a single administration Totality of data across the program at 6 months supports overall favorable product profile Initial three-month data
Read More

PDF Version
Read More
Summary Toggle

05.31.2019

Summary Toggle Axovant to Present at Upcoming Conferences in June

Summary ToggleBASEL, Switzerland , May 31, 2019 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (Nasdaq: AXGT), a clinical-stage company developing innovative gene therapies, today announced that Pavan Cheruvu, M.D., chief executive officer, will present at three conferences in June.
Read More

PDF Version
Read More
Summary Toggle

05.20.2019

Summary Toggle Axovant to Present at 2019 RBC Capital Markets Global Healthcare Conference

Summary ToggleBASEL, Switzerland , May 20, 2019 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (Nasdaq: AXGT), a clinical-stage company developing innovative gene therapies, today announced that Pavan Cheruvu, M.D., chief executive officer, will present at the 2019 RBC Capital Markets Global Healthcare
Read More

PDF Version
Read More
Summary Toggle

05.16.2019

Summary Toggle Axovant Announces Dosing of First Patient in Clinical Program for AXO-AAV-GM1, a Novel Gene Therapy for GM1 Gangliosidosis

Summary Toggle- Milestone marks the first patient with GM1 gangliosidosis treated with gene therapy- -Initial data expected in second half of 2019- -AXO-AAV-GM1 is Axovant’s third investigational gene therapy program to enter the clinic- BASEL, Switzerland , May 16, 2019 (GLOBE NEWSWIRE) -- Axovant Gene
Read More

PDF Version
Read More
Summary Toggle

05.07.2019

Summary Toggle Axovant Announces Reverse Share Split Effectiveness

Summary ToggleShares to begin trading on split-adjusted basis on May 8, 2019 BASEL, Switzerland , May 07, 2019 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (Nasdaq: AXGT), a clinical-stage company developing innovative gene therapies, today announced that a reverse share split of its common shares on a
Read More

PDF Version
Read More

Investors & Media Press Releases

Press Releases

Email Alerts

Print

Email

Search

Investors & Media Press Releases

Press Releases

Toolbar

Email Alerts

Print

Email

Search